Scott Kopetz
Impact in
- Oncology top 0.02%
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Pancreatic and Hepatic Oncology Research
- Hepatology top 0.1%
- Hepatocellular Carcinoma Treatment and Prognosis
Papers in
- Oncology 446
- Colorectal Cancer Treatments and Studies 348
- Cancer Immunotherapy and Biomarkers 61
- Cancer Treatment and Pharmacology 51
- Cancer Research 201
- Cancer Genomics and Diagnostics 180
- Co-authors
- Michael J. Overman (223 shared papers)Jean‐Nicolas Vauthey (53 shared papers)Dipen M. Maru (83 shared papers)Cathy Eng (92 shared papers)Jayesh Desai (43 shared papers)David G. Menter (56 shared papers)Heinz‐Josef Lenz (26 shared papers)Robert A. Wolff (62 shared papers)
- Journals
- Journal of Clinical Oncology (252 papers)Annals of Oncology (45 papers)Cancer Research (31 papers)Clinical Cancer Research (26 papers)Clinical Colorectal Cancer (15 papers)
- Partner nations
- United StatesItalySpain
In The Last Decade
Scott Kopetz
650 papers receiving 29.2k citations
Scott Kopetz's Hit Papers
Peers
Comparison fields: 5 of 151
- Oncology 16.0k
- Hepatology 3.8k
- Cancer Research 6.3k
- Pathology and Forensic Medicine 5.8k
- Pulmonary and Respiratory Medicine 4.5k
Countries citing papers authored by Scott Kopetz
This map shows the geographic impact of Scott Kopetz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scott Kopetz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scott Kopetz more than expected).
Fields of papers citing papers by Scott Kopetz
This network shows the impact of papers produced by Scott Kopetz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scott Kopetz. The network helps show where Scott Kopetz may publish in the future.
Co-authors
The 25 scholars most cited alongside Scott Kopetz, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 684 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study Hit paper breakdown → | 2017 | 2014 |
| 2 | Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer Hit paper breakdown → | 2018 | 1455 |
| 3 | Improved Survival in Metastatic Colorectal Cancer Is Associated With Adoption of Hepatic Resection and Improved Chemotherapy Hit paper breakdown → | 2009 | 1014 |
| 4 | Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer Hit paper breakdown → | 2017 | 680 |
| 5 | Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer Hit paper breakdown → | 2011 | 592 |
| 6 | Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF -Mutated Colorectal Cancer Hit paper breakdown → | 2015 | 520 |
| 7 | Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA Hit paper breakdown → | 2015 | 484 |
| 8 | Pathologic Response to Preoperative Chemotherapy: A New Outcome End Point After Resection of Hepatic Colorectal Metastases Hit paper breakdown → | 2008 | 431 |
| 9 | Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600–Mutant Colorectal Cancer Hit paper breakdown → | 2015 | 383 |
| 10 | 2009 | 378 | |
| 11 | Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018 Hit paper breakdown → | 2019 | 378 |
| 12 | Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study Hit paper breakdown → | 2021 | 344 |
| 13 | 2009 | 287 | |
| 14 | 2011 | 275 | |
| 15 | 2013 | 269 | |
| 16 | 2015 | 269 | |
| 17 | 2019 | 258 | |
| 18 | 2017 | 253 | |
| 19 | 2019 | 251 | |
| 20 | 2012 | 249 |
About Scott Kopetz
Scott Kopetz is a scholar working on Oncology, Cancer Research, Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine and Molecular Biology, having authored 684 papers that have together received 29.6k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (348 papers), Cancer Genomics and Diagnostics (180 papers), Genetic factors in colorectal cancer (168 papers), Lung Cancer Treatments and Mutations (97 papers), Cancer Immunotherapy and Biomarkers (61 papers), Cancer Treatment and Pharmacology (51 papers), Hepatocellular Carcinoma Treatment and Prognosis (46 papers) and Gastric Cancer Management and Outcomes (33 papers). The work is most often cited by research in Oncology (16.0k citations), Hepatology (3.8k citations), Cancer Research (6.3k citations), Pathology and Forensic Medicine (5.8k citations) and Pulmonary and Respiratory Medicine (4.5k citations). Scott Kopetz has collaborated with scholars based in United States, Italy and Spain. Frequent co-authors include Michael J. Overman, Jean‐Nicolas Vauthey, Dipen M. Maru, Cathy Eng, Jayesh Desai, David G. Menter, Heinz‐Josef Lenz, Robert A. Wolff, Thierry André and Christopher H. Lieu. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Cancer Research, Clinical Cancer Research and Clinical Colorectal Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.